Compare BIIB & BAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | BAP |
|---|---|---|
| Founded | 1978 | 1889 |
| Country | United States | Peru |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1B | 26.4B |
| IPO Year | 1996 | 1997 |
| Metric | BIIB | BAP |
|---|---|---|
| Price | $183.99 | $344.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 5 |
| Target Price | $197.46 | ★ $291.60 |
| AVG Volume (30 Days) | ★ 829.4K | 295.2K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 3.23% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.79 | N/A |
| Revenue | ★ $9,890,600,000.00 | N/A |
| Revenue This Year | N/A | $23.63 |
| Revenue Next Year | N/A | $8.78 |
| P/E Ratio | $20.92 | ★ $12.91 |
| Revenue Growth | ★ 2.22 | N/A |
| 52 Week Low | $110.04 | $165.51 |
| 52 Week High | $202.41 | $380.20 |
| Indicator | BIIB | BAP |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 54.91 |
| Support Level | $181.24 | $317.90 |
| Resistance Level | $184.16 | $360.83 |
| Average True Range (ATR) | 4.91 | 11.06 |
| MACD | -0.06 | 1.09 |
| Stochastic Oscillator | 59.95 | 82.15 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.